About Deep Genomics
Deep Genomics is an AI-driven drug discovery company focused on genetic medicines. The company leverages its Biological Foundation Model (BioFM) Platform to enable scalable molecular design and target biology discovery. This platform is designed to be reliable, reproducible, and accurate, facilitating the identification of molecules and targets that might otherwise be missed, thereby accelerating the development of life-changing medicines.
The company integrates AI with drug development through multilingual teams and technologies, supporting rapid iteration in both dry and wet lab environments. Deep Genomics aims to build, run, and improve BioFMs and Application Specific Models to enhance the drug discovery process. They offer a demo, RNAi Explorer, powered by DeepRNAi, to showcase the platform’s capability in predicting on- and off-target effects of siRNAs for various target genes.
Focus Areas
Business Intelligence
| Technology | BioFM Platform (Biological Foundation Models), AI Workbench, BigRNA (proprietary BioFM) |
What Physicians Need to Know
Deep Genomics' AI-driven platform aims to accelerate the discovery of life-changing genetic medicines by finding molecules and targets that might otherwise be missed. Their focus on reliable and reproducible molecular design, exemplified by tools like DeepRNAi for understanding siRNA effects, could lead to more precise and effective RNA therapies for various genetic conditions.
Videos
News, demos, and interviews about Deep Genomics.
Videos load interactively. If none appear, search YouTube for Deep Genomics →
Frequently Asked Questions
Investors
Who's funded Deep Genomics.
Related Companies
AIRA Health offers an AI-powered platform designed to accelerate clinical development by assisting biopharma teams with study design and protocol development. The platform acts as a unified environment where clinical, regulatory, and medical writing AI thought partners collaborate with human teams, adapting to the evolving study context. For physicians, AIRA aims to streamline the complex […]
Cymetica Biosciences develops AI systems and proprietary algorithms to optimize human health outcomes in real-time. Their work incorporates research from human space flight and its effects on the body, known as ‘space biosciences,’ and biological language modeling. The company constructs proprietary vector embeddings to fine-tune AI models, enabling them to extract not only known connections […]
ClinicalTrials.gov is a publicly accessible website and online database of clinical research studies, managed by the National Library of Medicine (NLM) at the National Institutes of Health (NIH). It serves as a central resource for patients, their families, healthcare professionals, and researchers to access comprehensive information on publicly and privately supported clinical studies across a […]
InsightRX is a healthcare AI company that provides precision medicine software for both healthcare providers and life sciences organizations. For physicians and clinical teams, InsightRX offers AI-powered tools that integrate pharmacometrics and real-world data to support smarter, more precise dosing decisions at the point of care. Their platform, which includes InsightRX Nova for Bayesian model-informed […]
Indica Labs is a global leader in AI-powered digital pathology software and services, providing comprehensive solutions for quantitative evaluation and management of whole slide images. Their flagship platforms, HALO® and HALO AI, leverage artificial intelligence and computer vision algorithms to enable fast and precise analysis of tissue samples, which is critical for advancing research and […]
Triomics is an oncology AI company dedicated to transforming how cancer centers manage complex clinical information. The company’s platform utilizes AI agents to meticulously read and interpret comprehensive longitudinal patient records, converting unstructured clinical data—such as notes, pathology reports, imaging results, and genomic panels—into structured, verifiable outputs. This process significantly reduces the manual burden on […]

